StockData
MiNK Therapeutics, Inc. logo

MiNK Therapeutics, Inc. (INKT) shareholders

INKTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$9.29−0.06 (-0.70%)

Close on Nov 17, 2026Market cap $47.38MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
4.0%
0M of 5M shares
Institutional holders
27
7 new, 3 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 9 sales
Net sold $119.89K

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Gkcc, LLC4,640,00011.79%13G (passive)May 14, 2024
Garo H. Armen3,514,3209.68%13D (active)Jan 16, 2024

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of INKTValueChange% of portfolio
Vanguard Capital Management LLC68,6601.35%$802.64K+9,2960.00%
DnB Asset Management AS55,1421.08%$644.61KNew0.00%
Longbow Finance SA16,6670.33%$194.84K–0.02%
Geode Capital Management, LLC15,5730.31%$182.08K−1,7720.00%
Citadel Advisors LLC15,4400.30%$180.49KNew0.00%
BlackRock, Inc.13,3820.26%$156.44K+7,1790.00%
Vanguard Fiduciary Trust Co8,2870.16%$96.88K–0.00%
UBS Group AG4,8850.10%$57.11K−10,3170.00%
Steward Partners Investment Advisory, LLC2,0000.04%$23.38K–0.00%
US Bancorp \de\1,9950.04%$23.32KNew0.00%
Paladin Partners, LLC1,0000.02%$11.69K–0.01%
Federation des caisses Desjardins du Quebec5000.01%$5.85KNew0.00%
Tower Research Capital LLC (TRC)4220.01%$4.93K+2660.00%
Covestor Ltd1190.00%$1.00K–0.00%
Osaic Holdings, Inc.1170.00%$1.37K+1160.00%
Morgan Stanley1130.00%$1.32K+90.00%
Barclays PLC240.00%$281New0.00%
Caitong International Asset Management Co., Ltd180.00%$210+80.00%
Northwestern Mutual Wealth Management Co180.00%$210–0.00%
Game Plan Financial Advisors, LLC160.00%$187–0.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026270M4.0%7 / 63 / 30M0M
Q1 2026230M2.5%5 / 24 / 50M0M
Q4 2025240M3.0%6 / 37 / 00M0M
Q3 2025180M1.8%2 / 62 / 30M0M
Q2 2025190M1.2%4 / 55 / 10M0M
Q1 2025160M0.9%16 / 00 / 00M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

10 funds held INKT in Q2 2026, 86% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of INKTValue% of fundAs of
Vanguard Total Stock Market Index Fund53,0701.04%$620.39K0.00%Jun 30, 2026
Vanguard Extended Market Index Fund15,3820.30%$179.82K0.00%Jun 30, 2026
iShares Micro-Cap ETF6,7340.13%$78.72K0.01%Jun 30, 2026
Fidelity Extended Market Index Fund6,5990.13%$80.51K0.00%May 31, 2026
Fidelity Nasdaq Composite Index Fund1,9020.04%$23.20K0.00%May 31, 2026
Fidelity Total Market Index Fund1,8830.04%$22.97K0.00%May 31, 2026
Fidelity Series Total Market Index Fund1,3890.03%$16.95K0.00%May 31, 2026
1290 VT Micro Cap Portfolio4450.01%$5.20K0.00%Jun 30, 2026
Vanguard Balanced Index Fund2080.00%$2.43K0.00%Jun 30, 2026
Blackstone Alternative Multi-Strategy Fund-200-0.00%-$2.34K-0.00%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Jennifer BuellChief Executive Officer, Director74,1951.45%Oct 14, 2026
Melissa OrilallPrincipal Financial Officer2220.00%Apr 9, 2026
Austin CharettePrincipal Accounting Officer400.00%Mar 23, 2026
Brian CorveseDirector54,7701.07%Sep 2, 2026
John Bradley HolcombDirector4,6910.09%Sep 2, 2026
Ulf WiinbergDirector51,7591.01%Sep 2, 2026
Barbara RyanDirector23,5910.46%Sep 2, 2026
Peter BehnerDirector24,4040.48%Sep 2, 2026
Robert Peter KadlecDirector19,1260.37%Dec 3, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Jennifer Buell
Chief Executive Officer, Director
Oct 12, 2026Sale−6,938$10.56$73.27K74,195
Jennifer Buell
Chief Executive Officer, Director
Oct 11, 2026Option exercise+23,191––81,133
John Bradley Holcomb
Director
Sep 1, 2026Award+1,233$10.95$13.50K4,691
Ulf Wiinberg
Director
Sep 1, 2026Award+1,279$10.95$14.01K23,929
Brian Corvese
Director
Sep 1, 2026Award+1,633$10.95$17.88K54,770
Peter Behner
Director
Sep 1, 2026Award+1,485$10.95$16.26K24,404
Barbara Ryan
Director
Sep 1, 2026Award+1,622$10.95$17.76K23,591
Barbara Ryan
Director
Jun 4, 2026Sale−500$12.68$6.34K22,969
Barbara Ryan
Director
Jun 4, 2026Sale−1,000$12.80$12.80K21,969
Ulf Wiinberg
Director
Jun 1, 2026Award+1,131$12.38$14.00K22,650
John Bradley Holcomb
Director
Jun 1, 2026Award+1,091$12.38$13.51K3,458
Barbara Ryan
Director
Jun 1, 2026Award+1,434$12.38$17.75K23,469
Brian Corvese
Director
Jun 1, 2026Award+1,444$12.38$17.88K53,137
Peter Behner
Director
Jun 1, 2026Award+1,313$12.38$16.25K22,919
Barbara Ryan
Director
Mar 10, 2026Sale−300$15.28$4.58K21,406
Barbara Ryan
Director
Mar 10, 2026Sale−500$15.57$7.79K20,906
Barbara Ryan
Director
Mar 10, 2026Sale−500$15.30$7.65K20,406
Barbara Ryan
Director
Mar 9, 2026Sale−200$10.17$2.03K21,706
Ulf Wiinberg
Director
Mar 2, 2026Award+1,285$10.90$14.01K21,519
John Bradley Holcomb
Director
Mar 2, 2026Award+1,239$10.90$13.51K2,367
Barbara Ryan
Director
Mar 2, 2026Award+1,629$10.90$17.76K22,035
Brian Corvese
Director
Mar 2, 2026Award+1,640$10.90$17.88K51,693
Peter Behner
Director
Mar 2, 2026Award+1,491$10.90$16.25K21,606
Barbara Ryan
Director
Mar 2, 2026Sale−100$10.83$1.08K21,906
Barbara Ryan
Director
Feb 27, 2026Sale−400$10.86$4.34K22,006
Jennifer Buell
Chief Executive Officer
Jan 2, 2026Tax withholding−10,024$11.12$111.47K57,942
Jennifer Buell
Chief Executive Officer
Jan 2, 2026Award+31,474$11.12$349.99K67,966
John Bradley Holcomb
Director
Dec 1, 2025Award+1,128$11.09$12.51K1,128
Peter Behner
Director
Dec 1, 2025Award+1,466$11.09$16.26K20,115
Robert Peter Kadlec
Director
Dec 1, 2025Award+1,218$11.09$13.51K19,126
Ulf Wiinberg
Director
Dec 1, 2025Award+1,263$11.09$14.01K20,234
Barbara Ryan
Director
Dec 1, 2025Award+1,601$11.09$17.76K22,406
Brian Corvese
Director
Dec 1, 2025Award+1,612$11.09$17.88K50,053
Jennifer Buell
Chief Executive Officer
Sep 9, 2025Tax withholding−5,351$15.36$82.19K36,492
Jennifer Buell
Chief Executive Officer
Sep 9, 2025Award+18,229$15.36$280.00K41,913
Barbara Ryan
Director
Sep 2, 2025Award+1,281$13.86$17.75K20,805
Robert Peter Kadlec
Director
Sep 2, 2025Award+975$13.86$13.51K17,908
Ulf Wiinberg
Director
Sep 2, 2025Award+1,011$13.86$14.01K18,971
Brian Corvese
Director
Sep 2, 2025Award+1,290$13.86$17.88K48,441
Peter Behner
Director
Sep 2, 2025Award+1,173$13.86$16.26K18,649
Brian Corvese
Director
Jun 2, 2025Award+2,494$7.17$17.88K47,151
Ulf Wiinberg
Director
Jun 2, 2025Award+1,953$7.17$14.00K17,960
Barbara Ryan
Director
Jun 2, 2025Award+2,476$7.17$17.75K19,524
Robert Peter Kadlec
Director
Jun 2, 2025Award+1,883$7.17$13.50K4,647
Peter Behner
Director
Jun 2, 2025Award+2,267$7.17$16.25K17,476
Brian Corvese
Director
Mar 3, 2025Award+2,033$8.79$17.87K44,657
Robert Peter Kadlec
Director
Mar 3, 2025Award+1,536$8.79$13.50K2,764
Barbara Ryan
Director
Mar 3, 2025Award+2,019$8.79$17.75K17,048
Ulf Wiinberg
Director
Mar 3, 2025Award+1,593$8.79$14.00K16,007
Peter Behner
Director
Mar 3, 2025Award+1,849$8.79$16.25K15,209
Robert Peter Kadlec
Director
Dec 1, 2024Award+12,286$0.73$8.97K12,286
Barbara Ryan
Director
Dec 1, 2024Award+24,229$0.73$17.69K150,336
Peter Behner
Director
Dec 1, 2024Award+20,987$0.73$15.32K133,634
Ulf Wiinberg
Director
Dec 1, 2024Award+20,476$0.73$14.95K144,181
Brian Corvese
Director
Dec 1, 2024Award+24,400$0.73$17.81K426,283
Ulf Wiinberg
Director
Sep 3, 2024Award+18,295$0.82$15.00K123,705
Barbara Ryan
Director
Sep 3, 2024Award+21,649$0.82$17.75K126,107
Peter Behner
Director
Sep 3, 2024Award+18,753$0.82$15.38K109,234
Brian Corvese
Director
Sep 3, 2024Award+21,802$0.82$17.88K405,296
Peter Behner
Director
Jun 3, 2024Award+15,454$0.99$15.30K90,481

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
1.14%
0M shares short
Days to cover
4.3
At 0M shares a day
Change since last report
+15.3%
From 0M shares
Short volume, 20 days
55.5%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of MiNK Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 5,483 shares on Oct 1, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Jennifer Buell
Officer, PRESIDENT AND CHIEF EXECUTIVE OFFICER
Oct 13, 20266,938$73.27KOct 12, 2026RESTRICTED STOCK UNITS VESTING
Agenus Inc.
Owner
Aug 29, 2025786,750$12.57MAug 29, 2025These shares were acquired in an original issuance from the issuer, which was incorporated as a wholly owned subsidiary of Agenus Inc.

See a number that looks wrong?